FindTrial
Sign In

SINGLE VERSUS DOUBLE AGONIST TRIGGER IN ANTAGONIST PROTOCOL CYCLES: A MULTICENTER RCT

SINGLE VERSUS DOUBLE AGONIST TRIGGER IN ANTAGONIST PROTOCOL CYCLES: A MULTICENTER RANDOMIZED CONTROLLED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202206698504097
Enrollment
160
Registered
2022-06-07
Start date
2022-06-15
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-male Fertility-female Infertility

Interventions

Double Dose
Single Dose

Sponsors

Department of Obstetrics and Gynaecology Faculty of Medicine Alexandria University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Women with a spontaneous normal menstrual cycle and a normal uterine cavity. Body mass index (BMI) < 35. Age less than 40. Average responders with AMH level above 1.2 ng/ml. All patients will be indicated for ICSI.

Exclusion criteria

Exclusion criteria: Comorbidities including, hypertension, Diabetes Mellitus or other endocrinopathies. Surgically retrieved sperms. Communicating hydrosalpinx if not treated. Cases with uterine abnormalities even if corrected. Poor responders. Polycystic ovary syndrome patients.

Design outcomes

Primary

MeasureTime frame
Ongoing pregnancy—

Secondary

MeasureTime frame
Oocyte maturity rate. ;Number of oocytes retrieved;Post-trigger serum luteinizing hormone (LH)—

Countries

Egypt

Contacts

Public ContactElsayedamr Basma

Patient Information Manager

elsayedamr@yahoo.com00201223106023

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026